Journal of Adolescent Health
Volume 37, Issue 6 , Pages 518-525 , December 2005

Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature

Presented at the annual meeting of Society for Pediatric Research/American Pediatric Society (SPR-APS), Baltimore, MD, May 2002.

  • Tomas J. Silber, M.D., M.A.S.S.

      Affiliations

    • Division of Adolescent Medicine, Children’s National Medical Center, George Washington University School of Medicine and Health Sciences, Washington, DC
    • Corresponding Author InformationTomas Jose Silber, M.D., M.A.S.S., Division of Adolescent Medicine, Children’s National Medical Center, 111 Michigan Avenue, NW, Washington, DC 20010.
    • ,
  • Adela Valadez-Meltzer, M.D., Ph.D.

      Affiliations

    • University of Maryland/Sheppard Pratt Psychiatry Residency Program, Baltimore, Maryland

Received 31 August 2004 ,Accepted 21 December 2004.

References 

  1. American College of Obstetrics and Gynecology . In: ACOG Practice Bulletin (Premenstrual Syndrome) . Washington, DC: American College of Obstetrics and Gynecology; 2000;p. 5
  2. American Psychiatric Association . In: DSM-III R. Diagnostic and Statistical Manual of Mental Disorders . 3rd ed.. Washington, DC: American Psychiatric Press; 1987; revised
  3. American Psychiatric Association . In: DSM-IV. Diagnostic and Statistical Manual of Mental Disorders . 4th ed.. Washington, DC: American Psychiatric Association; 1994;
  4. American Psychiatric Association . In: DSM-IV TR. Diagnostic and Statistical Manual of Mental Disorders . 4th ed.. Washington, DC: American Psychiatric Association; 2000; text revision
  5. Fisher M , Trieller K , Napolitano B . Premenstrual symptoms in adolescents . J Adolesc Health Care . 1989;10:369–375
  6. Wilson CA , Keye WR . A survey of adolescent dysmenorrhea and premenstrual symptom frequency (a model program for prevention, detection, and treatment) . J Adolesc Health Care . 1989;10:317–322
  7. Shye D , Jaffe B . Prevalence and correlates of perimenstrual symptoms (a study of Israeli teenage girls) . J Adolesc Health Care . 1991;12:217–224
  8. Raja SN , Feehan M , Stanton WR , McGee R . Prevalence and correlates of the premenstrual syndrome in adolescence . J Am Acad Child Adolesc Psychiatr . 1992;31:783–789
  9. Cleckner-Smith CS , Doughty AS , Grossman JA . Premenstrual symptoms (prevalence and severity in an adolescent sample) . J Adolesc Health . 1998;22:403–408
  10. Steiner M , Steinberg S , Stewart D , et al.   Fluoxetine in the treatment of premenstrual dysphoria . N Engl J Med . 1995;332: 1529–340
  11. Stone AB , Pearlstein TB , Brown WA . Fluoxetine in the treatment of late luteal phase dysphoric disorder . J Clin Psychiatr . 1991;52:290–293
  12. Wood SH , Mortola JF , Chan Y-F , et al.   Treatment of premenstrual syndrome with fluoxetine (a double-blind, placebo-controlled, crossover study) . Obstet Gynecol . 1992;80:339–344
  13. Menkes DB , Taghavi E , Mason PA , Howard RC . Fluoxetine’s spectrum of action in premenstrual syndrome . Int Clin Psychopharmacol . 1993;8:95–102
  14. Elks ML . Open trial of fluoxetine therapy for premenstrual syndrome . South Med J . 1993;86:503–507
  15. Brandenburg S , Tuynman-Qua H , Verheij R , Pepplinkhuizen L . Treatment of premenstrual syndrome with fluoxetine (an open study) . Int Clin Psychopharmacol . 1993;8:315–317
  16. Stewart DE , Fairman M , Barbadoro S , et al.   Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder . Biol Psychiatr . 1994;36:201–202
  17. Su T-P , Schmidt PJ , Danaceau MA , et al.   Fluoxetine in the treatment of premenstrual dysphoria . Neuropsychopharmacol . 1997;16:346–356
  18. Steiner M , Korzekwa M , Lamont J , Wilkins A . Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria . Psychopharmacol Bull . 1997;33:771–774
  19. Pearlstein TB , Stone AB . Long-term fluoxetine treatment of late luteal phase dysphoric disorder . J Clin Psychiatr . 1994;55:332–335
  20. Pearlstein TB , Stone AB , Lund SA , et al.   Comparison of fluoxetine, buproprion, and placebo in the treatment of premenstrual dysphoric disorder . J Clin Psychopharmacol . 1997;17:261–266
  21. Özeren S , Çorakçi A , Yücesoy I , et al.   Fluoxetine in the treatment of premenstrual syndrome . Eur J Obstet Gynecol Reprod Biol . 1997;73:167–170
  22. Diegoli MSC , da Fonesca AM , Diegoli CA , Pinotti JA . A double-blind trial of four medications to treat severe premenstrual syndrome . Int J Gynecol Obstet . 1998;62:63–67
  23. Wyatt KM , Dimmock PW , O’Brien PM . Premenstrual syndrome . Clinical Evidence . London: British Medical Journal Pub. Co; 2000;
  24. Wyatt KM , Dimmock PW , O’Brien PM . Selective serotonin reuptake inhibitors for premenstrual syndrome . Cochrane Database Syst Rev . 2002;4:CD001396
  25. Rapkin AJ . Progesterone metabolite allopregnanolone in women with PMS . Obstet Gynecol . 1997;90:709–714
  26. Freeman EW , Frye CA , Rickels K , et al.   Allopregnanolone levels and symptom improvement in severe premenstrual syndrome . J Clin Psychopharmacol . 2002;22:516–520
  27. Dimmock PW , Wyatt KM , Jones PW , O’Brien PM . Efficacy of selective serotonin-reuptake inhibitors in premenstrual syndrome . Lancet . 2000;356:1131–1136
  28. Yonkers KA , Halbreich U , Freeman  , et al.  Sertaline Premenstrual Dysphoric Collaborative Study Group   Symptomatic improvement of premenstrual dysphoric disorder with sertaline treatment. A randomized controlled trial . JAMA . 1997;278:983–988
  29. Eriksson E . Serotonin reuptake inhibitors for the treatment of premenstrual dysphoric disorders . Int Clin Psychopharmacol . 1999;14(suppl 2):S27
  30. Pearlstein TB , Stone AB , Lund SA , et al.   Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder . J Clin Psychopharm . 1997;17:261–266
  31. De la Gándara Martin JJ . Trastorno disfórico premenstrual (tratamiento a largo plazo con fluoxetina y discontinuación) . Actas Luso Esp Neurol Psiquiatr Cienc Afines . 1997;25:235–242
  32. Pearlstein T , Joliat MJ , Brown EB , Miner CM . Recurrences of symptoms of premenstrual dysphoric disorder after the cessation of luteal phase fluoxetine treatment . Am J Obstet Gynecol . 2003;188:887–895
  33. Roca CA , Schmidt PJ , Smith MJ , et al.   Effects of metergoline on symptoms in women with premenstrual dysphoric disorder . Am J Psychiatry . 2002;159:1876–1881
  34. Melke J , Westberg L , Landen M , et al.   Serotonin transporter gene polymorphins and platelet (3H) paroxetine binding in premenstrual dysphoria . Psychoneuroendocrinology . 2003;28:446–458
  35. Bixo M , Allard P , Backstrom T , et al.   Binding of [3H] paroxetine to serotonin uptake sites and of [3H] lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment . Psychoneuroendocrinology . 2001;26:551–564
  36. Cohen LS , Miner C , Brown EW , et al.   Premenstrual daily fluoxetine for premenstrual dysphoric disorder (a placebo-controlled, clinical trial using computerized diaries) . Obstet Gynecol . 2002;100:435–444
  37. Sundstrom-Poromaa I , Bixo M , Bjorn I , Nordh O . Compliance to antidepressant drug therapy for treatment of premenstrual syndrome . J Psychosom Obstet Gynecol . 2000;21:205–211
  38. Grady-Weliky TA . Clinical practice. Premenstrual dysphoric disorder . N Engl J Med . 2003;348:433–438
  39. Olah KS . The use of fluoxetine (Prozac) in premenstrual syndrome (is the incidence of sexual dysfunction and anorgasmia acceptable?) . J Obstet Gynecol . 2002;22:81–83
  40. Freeman EW , Rickels K , Sondheimer SJ , et al.   Continuous or intermittent dosing with sertaline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder . Am J Psychiatry . 2004;161:343–351
  41. Luisi AF , Pawasauskas JE . Treatment of premenstrual dysphoric disorder with selective serotonin reuptake inhibitors . Pharmacotherapy . 2003;23:1131–1140
  42. Halbreich U , Khan LS . Treatment of premenstrual dysphoric disorder with luteal phase dosing of sertraline . Expert Opin Pharmacother . 2003;4:2065–2078
  43. Miner C , Brown E , McCray S , et al.   Weekly luteal phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder (a randomized, double-blind, placebo-controlled clinical trial) . Clin Ther . 2002;24:417–433
  44. Freeman EW , Jabara S , Sondheimer SJ , Auletto R . Citalopram in PMS patients with prior SSRI treatment failure (a preliminary study) . J Womens Health Gend Based Med . 2002;11:459–464
  45. Jick H , Kaye JA , Jick SS . Antidepressants and the risk of suicidal behaviors . JAMA . 2004;292:338–343
  46. March J , Silva S , Petrycki S , et al.   Treatment for Adolescents With Depression Study (TADS) team. Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression (Treatment for Adolescents With Depression Study (TADS) randomized controlled trial) . JAMA . 2004;292:807–820
  47. Fluoxetine (Sarafem) for premenstrual dysphoric disorder . Med Lett . 2001;43:5–6
  48. Pearlstein T . Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder (the emerging gold standard?) . Drugs . 2002;62:1869–1885
  49. Hunter MS , Ussher JM , Browne SJ , et al.   A randomized comparison of psychological (cognitive behavior therapy), medical (fluoxetine) and combined treatment for women with premenstrual dysphoric disorder . J Psychosom Obstet Gynecol . 2002;23:193–199

PII: S1054-139X(04)00462-8

doi: 10.1016/j.jadohealth.2004.12.006

Journal of Adolescent Health
Volume 37, Issue 6 , Pages 518-525 , December 2005

Article Tools